BENGALURU, May 9 (Reuters) - Indian drugmaker Abbott

India reported a 24% rise in fourth-quarter profit on

Thursday, as strong sales outpaced the impact of government

pricing caps on certain medicines.

The company, which makes the popular antacid medicine

Digene, said its profit rose to 2.87 billion rupees ($34.3

million) for the three months ended March 31, from 2.31 billion

rupees a year earlier.

Revenues of drugmakers such as Abbott India and

GlaxoSmithKline Pharma India, which get most of their

business from India, have been impacted after the inclusion of

some of their drugs in the government's essential medicines list

in September 2022, making them susceptible to price caps.

Abbott, which is a unit of U.S. healthcare firm Abbott

Laboratories ( ABT ), has been trying to mitigate the impact of

pricing curbs by driving up sales and cutting back on expenses.

The company, which makes drugs including hypothyroidism

treatment tablets Thyronorm, said its revenue from operations

rose 7% to 14.39 billion rupees in the fourth quarter.

The company declared a dividend of 410 rupees per share for

fiscal year 2024.

($1 = 83.4760 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank

Dhaniwala)